ARPO - エアピオ・ファ―マシュ―ティカルズ (Aerpio Pharmaceuticals Inc.) エアピオ・ファ―マシュ―ティカルズ

 ARPOのチャート


 ARPOの企業情報

symbol ARPO
会社名 Aerpio Pharmaceuticals Inc (エアピオ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Aerpio Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha) which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14 2017 the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14 2017 the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.   エアピオ・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。主に眼疾患の治療薬の開発に注力する。主要パイプラインのAKB-9778は、血管透過性制御に関わるTie2シグナル伝達経路により糖尿病網膜症の治療に有効。また、加齢黄斑変性症や糖尿病性黄斑浮腫の治療薬ARP-1536や、炎症性腸疾患のためのAKB-4924がある。本社所在地はオハイオ州シンシナティ。   Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 16, 2007 and is headquartered in Cincinnati, OH.
本社所在地 9987 Carver Road Cincinnati OH 45242 USA
代表者氏名
代表者役職名
電話番号 +1 513-985-1920
設立年月日 39387
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 25人
url www.aerpio.com
nasdaq_url https://www.nasdaq.com/symbol/arpo
adr_tso
EBITDA EBITDA(百万ドル) -24.51039
終値(lastsale) 3.05
時価総額(marketcap) 123768563.85
時価総額 時価総額(百万ドル) 113.62360
売上高 売上高(百万ドル) 1.33333
企業価値(EV) 企業価値(EV)(百万ドル) 44.84039
当期純利益 当期純利益(百万ドル) -24.30012
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Aerpio Pharmaceuticals Inc revenues increased from $0K to $1.3M. Net loss applicable to common stockholders increased 17% to $13.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research_Development - Balancing value increase of 54% to $8.1M (expense).

 ARPOのテクニカル分析


 ARPOのニュース

   Diabetic Nephropathy Market SWOT Analysis by Key Players Daiichi Sankyo, Aerpio Pharmaceuticals, Aibios, Algomedix  2020/09/28 05:21:59 OpenPR
Latest document on 'Diabetic Nephropathy - Pipeline Review, H2 2020' is added in HTF MI research reporsitory provides in-depth analysis, Competitive scenario, and future market trends and strategies. The regional analysis includes countries like USA, Germany, China, France, Japan,
   The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal  2020/08/14 12:26:21 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 13) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Fulgent Genetics Inc (NASDAQ: FLGT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Inozyme Pharma Inc (NASDAQ: INZY ) iTeos Therapeutics Inc (NASDAQ: ITOS ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Natera Inc (NASDAQ: NTRA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Orthopediatrics Corp (NASDAQ: KIDS ) Penumbra Inc (NYSE: PEN ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Silk Road Medical Inc (NASDAQ: SILK ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Vaxcyte Inc (NASDAQ: PCVX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 13) Entera Bio Ltd (NASDAQ: ENTX ) Forma Therapeutics Holdings Inc (NASDAQ: FMTX )(reacted to its second-quarter results) Lantern Pharma Inc. (NASDAQ: LTRN ) NanoVibronix Inc (NASDAQ: NAOV ) Recro Pharma Inc (NASDAQ: REPH ) Stocks In Focus Novavax Agrees to Supply 60M Doses of Coronavirus Vaccine to U.K. Novavax, Inc. (NASDAQ: NVAX ) said it has signed a term sheet with the U.K. for supplying 60 million doses of NVX-CoV2373, its COVID-19 vaccine candidate.
   Aerpio Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 12  2020/08/10 12:00:00 GlobeNewswire
CINCINNATI, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing…
   The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO  2020/08/06 07:57:00 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) ABIOMED, Inc. (NASDAQ: ABMD) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) (announced a U.S. …
   Thinking about buying stock in Sorrento Therapeutics, Aerpio Pharmaceuticals, Horizon Therapeutics, Riot Blockchain, or Royal Caribbean Cruises?  2020/08/05 13:38:00 PR Newswire
NEW YORK, Aug. 5, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRNE, ARPO, HZNP, RIOT, and RCL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Aerpio Pharmaceuticals : A Novel Mechanism for the Treatment of Glaucoma Presented Jun 2020 | MarketScreener  2020/06/15 14:17:19 MarketScreener
Novel Mechanism for the Treatment of Glaucoma • Introductions • Paul… | June 15, 2020
   The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant  2020/05/29 11:22:24 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO )( announced a collaboration study for razuprotafib in COVID-19 treatment) Aileron Therapeutics Inc (NASDAQ: ALRN ) Arca Biopharma Inc (NASDAQ: ABIO ) ( reacted to its planned foray into COVID-19 treatment) argenx SE – ADR (NASDAQ: ARGX ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) ChemoCentryx Inc (NASDAQ: CCXI ) GENMAB A/S/S ADR (NASDAQ: GMAB )(announced positive topline Phase 3 data for daratumumab in light-chain amyloidosis) Imara Inc NASDAQ: (IMRA) Liquidia Technologies Inc (NASDAQ: LQDA ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Qiagen NV (NYSE: QGEN ) Tenax Therapeutics Inc (NASDAQ: TENX ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Vermillion, Inc. (NASDAQ: VRML ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 28) Zafgen Inc (NASDAQ: ZFGN ) Stocks In Focus Karyopharm to Present Positive Selinexor Data In Multiple Myeloma Patients At ASCO Karyopharm Therapeutics Inc (NASDAQ: KPTI ) announced detailed results from the pivotal Phase 3 BOSTON study that evaluated once-weekly selinexor in combination with once-weekly Velcade and low-dose dexamethasone, or SVd, compared to the standard twice-weekly Velcade plus low-dose dexamethasone, or Vd, in second-line to fourth-line setting in multiple myeloma patients.
   General Electric : Thinking about buying stock in Aerpio Pharmaceuticals, Axcella Health, General Electric, Zomedica Pharmaceuticals, or Avis Budget Group? | MarketScreener  2020/05/28 13:32:09 MarketScreener
NEW YORK, May 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARPO, AXLA, GE, ZOM, and CAR. … | May 28, 2020
   Is Aerpio Pharmaceuticals (ARPO) Outperforming Other Medical Stocks This Year?  2020/05/27 15:30:18 Zacks Investment Research
Is (ARPO) Outperforming Other Medical Stocks This Year?
   Is Aerpio Pharmaceuticals (ARPO) Stock Outpacing Its Medical Peers This Year?  2020/05/11 15:30:14 Zacks Investment Research
Is (ARPO) Outperforming Other Medical Stocks This Year?
   Aerpio Pharmaceuticals : A Novel Mechanism for the Treatment of Glaucoma Presented Jun 2020 | MarketScreener  2020/06/15 14:17:19 MarketScreener
Novel Mechanism for the Treatment of Glaucoma • Introductions • Paul… | June 15, 2020
   The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant  2020/05/29 11:22:24 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO )( announced a collaboration study for razuprotafib in COVID-19 treatment) Aileron Therapeutics Inc (NASDAQ: ALRN ) Arca Biopharma Inc (NASDAQ: ABIO ) ( reacted to its planned foray into COVID-19 treatment) argenx SE – ADR (NASDAQ: ARGX ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) ChemoCentryx Inc (NASDAQ: CCXI ) GENMAB A/S/S ADR (NASDAQ: GMAB )(announced positive topline Phase 3 data for daratumumab in light-chain amyloidosis) Imara Inc NASDAQ: (IMRA) Liquidia Technologies Inc (NASDAQ: LQDA ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Qiagen NV (NYSE: QGEN ) Tenax Therapeutics Inc (NASDAQ: TENX ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Vermillion, Inc. (NASDAQ: VRML ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 28) Zafgen Inc (NASDAQ: ZFGN ) Stocks In Focus Karyopharm to Present Positive Selinexor Data In Multiple Myeloma Patients At ASCO Karyopharm Therapeutics Inc (NASDAQ: KPTI ) announced detailed results from the pivotal Phase 3 BOSTON study that evaluated once-weekly selinexor in combination with once-weekly Velcade and low-dose dexamethasone, or SVd, compared to the standard twice-weekly Velcade plus low-dose dexamethasone, or Vd, in second-line to fourth-line setting in multiple myeloma patients.
   General Electric : Thinking about buying stock in Aerpio Pharmaceuticals, Axcella Health, General Electric, Zomedica Pharmaceuticals, or Avis Budget Group? | MarketScreener  2020/05/28 13:32:09 MarketScreener
NEW YORK, May 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARPO, AXLA, GE, ZOM, and CAR. … | May 28, 2020
   Is Aerpio Pharmaceuticals (ARPO) Outperforming Other Medical Stocks This Year?  2020/05/27 15:30:18 Zacks Investment Research
Is (ARPO) Outperforming Other Medical Stocks This Year?
   Is Aerpio Pharmaceuticals (ARPO) Stock Outpacing Its Medical Peers This Year?  2020/05/11 15:30:14 Zacks Investment Research
Is (ARPO) Outperforming Other Medical Stocks This Year?

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エアピオ・ファ―マシュ―ティカルズ ARPO Aerpio Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)